Clinical trials: Smoldering Plasma Cell Myeloma, active
Monoclonal Gammopathy of Undetermined Significance, Smoldering Plasma Cell Myeloma
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
The goal of this study is to find markers that may help to predict why some patients who have monoclonal gammopathy of unknown significance (MGUS) or smoldering multiple myeloma (SMM) that have no signs or symptoms of disease…
- Trial name
- NCT02726750
- Testing
- Biospecimen Collection, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Smoldering Multiple Myeloma
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
This research study is studying a targeted therapy as a possible treatment for Smoldering Multiple Myeloma. The following intervention will be involved in this study: Lenalidomide Citarinostat (CC-96241) PVX-410
- Trial name
- NCT02886065
- Testing
- Hiltonol, Citarinostat, Lenalidomide
- Where
- 6 sites in United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts General Hospital
Smoldering Plasma Cell Myeloma
Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)
This is a multi-center, open label, phase II study designed to evaluate the efficacy of isatuximab with or without lenalidomide when given to patients with high risk smoldering multiple myeloma.
- Trial name
- NCT02960555
- Testing
- Isatuximab, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Monoclonal Gammopathy of Undetermined Significance, Smoldering Plasma Cell Myeloma
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
This study examines the quality of life in patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma.
- Trial name
- NCT05136807
- Testing
- Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma, Amyloidosis
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed consent form (ICF) will be included in this study.
- Conditions
- Multiple Myeloma, Amyloidosis, Cryoglobulinemia, Castleman's Disease
- Trial name
- NCT05283993
- Testing
- No intervention
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Smoldering Plasma Cell Myeloma
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma.
- Trial name
- NCT03937635
- Testing
- Daratumumab, Dexamethasone, Lenalidomide
- Where
- 748 sites in United States, Puerto Rico
- Volunteers
- 288 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Smoldering Plasma Cell Myeloma
Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
This pilot early phase I trial studies pembrolizumab in treating patients with slow growing (smoldering) multiple myeloma with intermediate or high-risk of spreading.
- Trial name
- NCT02603887
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma, Multiple Myeloma Progression
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and…
- Conditions
- Multiple Myeloma, Multiple Myeloma Progression, Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)
- Trial name
- NCT06644625
- Testing
- Blood draw for the laboratory assessment
- Where
- United States
- Volunteers
- 1,665 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Smoldering Plasma Cell Myeloma
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
This phase II trial studies the effects of iberdomide when given alone or in combination with dexamethasone in treating intermediate or high-risk smoldering multiple myeloma patients.
- Trial name
- NCT04776395
- Testing
- Dexamethasone, Iberdomide Hydrochloride, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Emory University
Multiple Myeloma, Waldenstrom's Macroglobulinemia
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
The purpose of this study is to obtain bone marrow and peripheral blood samples, along with clinical data from patients with Multiple Myeloma (MM), Waldenstrom's Macroglobulinemia (WM), Smoldering MM, and other lymphoplasmacytic…
- Conditions
- Multiple Myeloma, Waldenstrom's Macroglobulinemia, Smoldering Multiple Myeloma, Lymphoblastic Lymphoma
- Trial name
- NCT01177527
- Where
- United States
- Volunteers
- 656 people
- Sponsor
- Dana-Farber Cancer Institute
Smoldering Plasma Cell Myeloma
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma.
- Trial name
- NCT05014646
- Testing
- Cholestyramine, Leflunomide
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- City of Hope Medical Center
Smoldering Plasma Cell Myeloma
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma
This pilot trial studies how well leflunomide works for the treatment of patients with high-risk smoldering plasma cell myeloma, for the delay of disease progression.
- Trial name
- NCT04370483
- Testing
- Leflunomide, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma, Smoldering Multiple Myeloma
European Myeloma Network (EMN) Sample Project
This is an observational, non-interventional, multicenter study for the prospective collection, storage and analysis of patients' biological samples.
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Plasma Cell Leukemia, Extramedullary Myeloma
- Trial name
- EMN36 (NCT06237803)
- Testing
- storage of biological samples
- Where
- 41 sites in Australia, Austria and 8 more
- Volunteers
- 6,000 people
- Sponsor
- European Myeloma Network B.V.
Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
This clinical trial investigates the effect of non-chemotherapeutic interventions in patients with multiple myeloma or MDS. Non-chemotherapeutic interventions such as physical activity and nutritional interventions (e.g.…
- Conditions
- Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
- Trial name
- NCT05312255
- Testing
- Behavioral Intervention, Beta-Adrenergic Antagonist, Propranolol
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Roswell Park Cancer Institute
Multiple Myeloma, Amyloidosis
Registry for Adults With Plasma Cell Disorders (PCD's)
The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (MM), who complete the assessment, previously known as a "geriatric…
- Conditions
- Multiple Myeloma, Amyloidosis, Cryoglobulinemia, Castleman's Disease
- Trial name
- NCT03717844
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Plasma Cell Dyscrasias
The Indiana Myeloma Registry
This is a prospective, non-interventional, observational study. The purpose of this study is to collect data and bio-specimens that will support future research
- Trial name
- NCT03616483
- Testing
- This is a non-interventional trial
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Indiana University
Smoldering Multiple Myeloma
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Selinexor is a drug that has been approved in the treatment of patients with symptomatic multiple myeloma. The standard of care for patients with Smoldering Multiple Myeloma remains observation, but there are numerous clinical…
- Trial name
- NCT05597345
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Rochester
Smoldering Multiple Myeloma
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
This study evaluates the use of carfilzomib, lenalidomide, daratumumab, and dexamethasone in subjects with high-risk smoldering multiple myeloma (SMM).
- Trial name
- ASCENT (NCT03289299)
- Testing
- Carfilzomib, Lenalidomide, Daratumumab
- Where
- 10 sites in United States
- Volunteers
- 87 people
- Sponsor
- International Myeloma Foundation